Strausberg RL, Schreiber SL. From knowing to controlling: a path from genomics to drugs using small molecule probes. Science. 2003;300(5617):294-5. doi:10.1126/science.1083395.

Steele FR. Big Pharma’s Commedia. Cell. 2005;123(6):971-3. doi:10.1016/j.cell.2005.11.033.

Scolnick E. Program to improve cognitive functioning in patients with schizophrenia: reflections. Schizophr Res. 2004;72(1):75-7. doi:10.1016/j.schres.2004.09.005.

Greulich H, Pollock PM. Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med. 2011;17(5):283-92. doi:10.1016/j.molmed.2011.01.012.

Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-7. doi:10.1038/nature11003.

Daley GQ. The promise and perils of stem cell therapeutics. Cell Stem Cell. 2012;10(6):740-9. doi:10.1016/j.stem.2012.05.010.

Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12(8):581-94. doi:10.1038/nrd4051.

McShane LM, Cavenagh MM, Lively TG, et al. Criteria for the use of omics-based predictors in clinical trials. Nature. 2013;502(7471):317-20. doi:10.1038/nature12564.

Kwiatkowski DJ, Wagle N. mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?. EBioMedicine. 2015;2(1):2-4. doi:10.1016/j.ebiom.2014.12.011.

McNeish J, Gardner JP, Wainger BJ, Woolf CJ, Eggan K. From Dish to Bedside: Lessons Learned While Translating Findings from a Stem Cell Model of Disease to a Clinical Trial. Cell Stem Cell. 2015;17(1):8-10. doi:10.1016/j.stem.2015.06.013.